A CLINICAL TRIAL TO STUDY THE EFFECT OF SIDDHA DRUG THEER ANDHASKHAN MATHIRAI IN PATIENTS HAVING RHEUMATOID ARTHRITIS

PHASE II NON-RANDOMIZED OPEN CLINICAL EVALUATION OF SIDDHA DRUG THEER ANDHASKHAN MATHIRAI FOR UTHIRAVAATHA SURONITHAM (RHEUMATOID ARTHRITIS)-IN BOTH GENDER OF AGE BETWEEN 18 TO 50 YEARS PATIENTS ATTENDING OPD AT AAGHIM ATTACHED WITH GSMC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020797

Enrollment

Registered

2019-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

Intervention1: THEER ANDHASKHAN MATHIRAI: 130mg of Theer andhaskhan mathirai is administered twice a day with jaggery for 48 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Age limit - 18 to 50 years Both the Gender(Even though a female specific disorder) Morning stiffness more than 1 hour Arthritis of hand joints Arthritis of 3 or more joints Symmetrical arthritis Anti-cyclic citrullinated Peptide (Anti CCP) Positive

Exclusion criteria

Exclusion criteria: Age below 18 and above 50 years Rheumatic fever Psoriatic arthropathy Reiters syndrome Gouty arthritis Systemic Lupus Erythematosus Progressive systemic sclerosis Pregnant women and lactating mothers Any other serious systemic illness will be excluded clinically or based on medical reports

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by reduction in clinical symptoms measured by Arthritic pain scaleTimepoint: 48 Days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Naveen kumar R

Government Siddha Medical College

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026